Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00810
|
|||||
| Drug Name |
Ziprasidone
|
|||||
| Synonyms |
Geodon; 146939-27-7; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; 6UKA5VEJ6X; C21H21ClN4OS; CHEBI:10119; CHEMBL708; CP 88059; CP 88059-01; CP-88,059; CP-88,059-01; CP-88,059-1; CP-88059-1; DSSTox_CID_3753; DSSTox_GSID_23753; DSSTox_RID_77186; Geodon; Geodon (TN); TC-5280; UNII-6UKA5VEJ6X; Zeldox; Zeldox (TN); Zipradon; Zipradon (TN); Ziprasidona; Ziprasidone (INN); Ziprasidone [INN:BAN]; Ziprasidone hydrochloride; Ziprasidone mesylate trihydrate; Ziprasidonum; Ziprazidone; ziprasidona; ziprasidonum; ziprazidone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11: 6A20] | Approved | [1] | |||
| Therapeutic Class |
Antipsychotic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H21ClN4OS
|
|||||
| Canonical SMILES |
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
|
|||||
| InChI |
InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
|
|||||
| InChIKey |
MVWVFYHBGMAFLY-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 146939-27-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 412.9 | Topological Polar Surface Area | 76.7 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:10119
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ziprasidone was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.